Iterion welcomes new Chief Operating Officer, Jean Chang
Iterion Therapeutics hires Jean Chang as Chief Operating Officer.
Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors
Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.